Neutrophil Extracellular Traps Mediate Antiphospholipid Antibody-induced Pregnancy Loss
NCT ID: NCT03735108
Last Updated: 2018-11-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2018-11-01
2019-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
2. Comparing the expression levels of neutrophil extracellular traps in peripheral blood and decidua of patients with antiphospholipid antibody-induced pregnancy loss and normal control group;
3. Comparing the expression levels of neutrophil extracellular traps in peripheral blood and decidua of mice with antiphospholipid antibody-induced pregnancy loss and normal control group;
4. After treatment of antiphospholipid antibody-induced mouse abortion model with metformin,the effect of metformin on embryo loss rate and viable embryo body weight was observed.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Establish the Referenc Range of Antiphospholipid Antibody in Healthy Preganany Women
NCT05883189
Patients Pregnant Women With or Without Primary Antiphospholipid Antibody Syndrome
NCT05786235
Antiphospholipid Antibodies and Early Severe Preeclampsia.
NCT01538121
Effect of Rheumatic Heart Disease on Maternal and Fetal Outcomes
NCT03029117
The Novel Immunomodulatory and Anticoagulant Therapies for Recurrent Pregnancy Loss
NCT02990403
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
pregnancy loss group
the times of pregnancy loss more than or equal to twice
No interventions assigned to this group
normal control group
no history of pregnancy loss
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical diagnosis of Antiphospholipid syndrome
Exclusion Criteria
* Hematopoietic system diseases
* Cardiovascular system diseases
* Gastrointestinal system diseases
* Urinary system diseases
* Nervous system or mental diseases
* Have taken other drugs recently
25 Years
41 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai First Maternity and Infant Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shihua Bao
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai First Maternity and Infant Hospital
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ShanghaiFMIH Shihua Bao
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.